LARIMAR THERAPEUTICS, INC. (LRMR) Free cash flow 2016–2025
LARIMAR THERAPEUTICS, INC. (LRMR) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$113.3MFY2025 · since FY2016: -$52.6M → -$113.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$113.3M | -59.0% |
| FY2024 | -$71.3M | -112.0% |
| FY2023 | -$33.6M | -21.5% |
| FY2022 | -$27.7M | +34.8% |
| FY2021 | -$42.4M | -0.4% |
| FY2020 | -$42.3M | -85.5% |
| FY2019 | -$22.8M | +55.8% |
| FY2018 | -$51.6M | -17.7% |
| FY2017 | -$43.8M | +16.7% |
| FY2016 | -$52.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More LRMR financial trends
LRMR RevenueLRMR Net incomeLRMR Net marginLRMR Gross profitLRMR Gross marginLRMR Operating incomeLRMR Operating marginLRMR Operating cash flowLRMR Capital expendituresLRMR Return on equityLRMR Stock buybacksLRMR Dividends paidLRMR Total assetsLRMR Total liabilitiesLRMR Shareholders’ equityLRMR overview →